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ISSOBJECTIVES The authors sought to evaluate the prognostic significance of baseline N-terminal pro–B-type
natriuretic peptide (NT-proBNP), whether NT-proBNP modified the treatment response to sacubitril/valsartan, and the
treatment effect of sacubitril/valsartan on NT-proBNP overall and in key subgroups.
BACKGROUND Sacubitril/valsartan reduces NT-proBNP in heart failure (HF) with both reduced and preserved ejection
fraction (EF), but did not significantly reduce total HF hospitalizations and cardiovascular death compared with
valsartan in patients with HF with preserved EF (HFpEF).
METHODS In the PARAGON-HF (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in
Heart Failure Patients With Preserved Ejection Fraction) trial, 4,796 patients with HFpEF and elevated NT-proBNP
were randomized to sacubitril/valsartan or valsartan. NT-proBNP was measured at screening in all patients and at
5 subsequent times in >2,700 patients: before, between, and after sequential valsartan and sacubitril/valsartan run-in
periods, and 16 and 48 weeks post-randomization.
RESULTS Median NT-proBNP was 911 pg/ml (interquartile range: 464 to 1,613 pg/ml) at screening. Screening
NT-proBNP was strongly associated with the primary endpoint, total HF hospitalizations and cardiovascular death (rate
ratio [RR]: 1.68 per log increase in NT-proBNP, 95% confidence interval [CI]: 1.53 to 1.85; p < 0.001). This relationship
was stronger in patients with atrial fibrillation (adjusted RR: 2.33 [95% CI: 1.89 to 2.87] vs. 1.58 [95% CI: 1.42 to 1.75]
in patients without atrial fibrillation; p interaction <0.001) and weaker in obese patients (adjusted RR: 1.50 [95%
CI: 1.31 to 1.71] vs. 1.92 [95% CI: 1.70 to 2.17] in nonobese patients; p interaction <0.001). Screening NT-proBNP did not
modify the treatment effect of sacubitril/valsartan compared with valsartan (p interaction ¼ 0.96). Sacubitril/
valsartan reduced NT-proBNP by 19% (95% CI: 14% to 23%; p < 0.001) compared with valsartan 16 weeks post-
randomization, with similar reductions in men (20%) and women (18%), and in patients with left ventricular EF #57%
(20%) and >57% (18%). Decreases in NT-proBNP predicted lower subsequent risk of the primary endpoint.
CONCLUSIONS Baseline NT-proBNP predicted HF events but did not modify the sacubitril/valsartan treatment effect
in patients with HFpEF. Sacubitril/valsartan reduced NT-proBNP consistently in men and women, and in patients with
lower or higher EF. (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart
Failure Patients With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711) (J Am Coll Cardiol HF 2020;8:372–81)
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AB BR E V I A T I O N S
AND ACRONYM S
adj. = adjusted
CI = confidence interval
CV = cardiovascular
HF = heart failure
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373N atriuretic peptides play key roles in theregulation of volume status and hemody-namics in patients with heart failure (HF)
(1). Elevated plasma levels are useful for diagnosis
and prognosis in HF (2,3). Sacubitril inhibits the endo-
peptidase neprilysin, which is responsible for degra-
dation of vasoactive peptides including natriureticSEE PAGE 382
HFpEF = heart failure with
preserved ejection fraction
LVEF = left ventricular
ejection fraction
NT-proBNP = N-terminal pro–
B-type natriuretic peptide
NYHA = New York Heart
Association
RR = rate ratiopeptides, thereby increasing their plasma levels
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374sacubitril/valsartan on clinical outcomes. We also
examined the effect of sacubitril/valsartan on NT-
proBNP and the association between change in NT-
proBNP and outcomes.
METHODS
STUDY DESIGN AND PATIENT POPULATION. The
PARAGON-HF trial was a multicenter, randomized,
double-blind trial comparing sacubitril/valsartan with
valsartan in patients with chronic HF, LVEF $45%,
elevated NT-proBNP levels, and evidence of struc-
tural heart disease. The study design has been
described in detail previously (10). Inclusion criteria
included age $50 years, New York Heart Association
(NYHA) functional class II to IV, either left ventricular
hypertrophy or left atrial enlargement by echocar-
diogram, and diuretic use for at least 30 days.
Screening visit NT-proBNP level >200 pg/ml for pa-
tients with HF hospitalization in the prior 9 months
and >300 pg/ml for patients who had not been hos-
pitalized was required; these thresholds were
increased 3-fold for patients with atrial fibrillation on
screening visit electrocardiogram.
Patients were exposed to sequential valsartan and
sacubitril/valsartan run-in periods before randomi-
zation. During the 1- to 2-week valsartan run-in, val-
sartan 40 mg or 80 mg was administered twice daily;
patients receiving the lower dose initially were
increased to 80 mg twice daily. Patients tolerating
valsartan were then exposed to a 2- to 4-week run-in
period during which they received sacubitril/valsar-
tan 49/51 mg twice daily. Only patients who tolerated
both study drugs were eligible for randomization.
During the double-blind follow-up period, doses were
increased to sacubitril/valsartan 97/103 mg twice
daily or valsartan 160 mg twice daily when possible.
CLINICAL ENDPOINTS. The primary efficacy
endpoint was a composite of total (first and recurrent)
HF hospitalizations and CV death. Key secondary
endpoints included components of the primary
outcome and all-cause mortality. A blinded clinical
events committee at Brigham and Women’s Hospital
(Boston, Massachusetts) adjudicated these endpoints.
NT-proBNP MEASUREMENTS. Plasma NT-proBNP
was measured in central laboratories from samples
collected at individual sites. Screening visit samples
(n ¼ 4,757, 99% of patients) were analyzed to deter-
mine study eligibility at 9 regional laboratories owned
by or affiliated with the central laboratory (Clinical
Reference Laboratory, Lenexa, Kansas) with the Roche
proBNP II (Roche Diagnostics, Penzberg, Germany) or
the Siemens Immulite 1000 (Siemens, Munich,Germany) assays. Intraday and interday assay varia-
tion coefficients for all regional labs were #15%.
Measurements were made at 5 subsequent times in
>2,700 patients: before the valsartan run-in period
(n ¼ 2,774), between the run-in periods (n ¼ 3,247),
randomization (n ¼ 3,330), and 16 weeks (n ¼ 1,651 in
the sacubitril/valsartan arm and 1,593 in the valsartan
arm) and 48weeks (n¼1,564 in sacubitril/valsartan arm
and 1,494 in valsartan arm) after randomization.
Samples from these 5 visits were analyzed in 2 fully
harmonized central laboratories (Clinical Reference
Laboratory, Lenexa, Kansas, and KingMed, Guangz-
hou, China) from plasma stored long-term at 80oC.
Samples were analyzed in complete patient sets, in
duplicate, with the Roche proBNP II assay. Intraday
and interday assay variation coefficients were #2.5%
and #3.2%, respectively. The analytic measurement
range was 25 to 35,000 pg/ml.
STATISTICAL ANALYSIS. NT-proBNP levels were
presented as median (interquartile range) or geo-
metric mean (95% confidence interval [CI]). Changes
in NT-proBNP were described using geometric mean
and compared between the sacubitril/valsartan and
valsartan arms overall and in key subgroups. NT-
proBNP levels and changes were log-transformed
due to right-skewed distributions. Baseline charac-
teristics of patients in each of 4 quartiles of screening
visit NT-proBNP and NT-proBNP change were
described using proportions for categorical variables,
mean and SD for normally distributed continuous
variables, and median and interquartile range for
skewed continuous variables, including NT-proBNP.
These characteristics were compared by trend using
parametric and nonparametric tests, as appropriate.
We evaluated the association between screening
NT-proBNP level and the primary endpoint of total
(first and recurrent) HF hospitalizations and CV death
using the semiparametric proportional rates method
of Lin et al. (11), adjusted for 21 relevant covariates:
age; sex; race; region; history of diabetes, stroke, and
myocardial infarction; ischemic cause of HF; NYHA
functional class; prior HF hospitalization; medica-
tions (angiotensin-converting enzyme inhibitor/
angiotensin receptor blocker, mineralocorticoid
antagonist, diuretic agent, and beta-blocker); atrial
fibrillation on screening electrocardiogram; body
mass index; LVEF; systolic and diastolic blood pres-
sure; serum potassium; and estimated glomerular
filtration rate. Modification of the effect of sacubitril/
valsartan on the primary endpoint by NT-proBNP was
assessed by the interaction term between screening
NT-proBNP and sacubitril/valsartan (vs. valsartan)
treatment allocation, with and without adjustment
TABLE 1 Baseline Characteristics of Patients by Screening Visit NT-proBNP Quartile
Quartile 1
(n ¼ 1,190)
Quartile 2
(n ¼ 1,189)
Quartile 3
(n ¼ 1,189)
Quartile 4
(n ¼ 1,189) p Value
NT-proBNP, pg/ml 12.5–464 465–911 912–1,613 1,617–31,522
Age, yrs 70.8  8.4 72.6  8.4 73.3  8.2 74.4  8.3 <0.001
Female 662 (55.6) 629 (52.9) 559 (47.0) 604 (50.8) 0.002
Race 0.85
White 964 (81.0) 955 (80.3) 995 (83.7) 958 (80.6)
Asian 144 (12.1) 156 (13.1) 140 (11.8) 166 (14.0)
Black 25 (2.1) 34 (2.9) 18 (1.5) 23 (1.9)
Other 57 (4.8) 44 (3.7) 36 (3.0) 42 (3.5)
Region
Asia/Pacific and other 181 (15.2) 197 (16.6) 174 (14.6) 206 (17.3) 0.05
Central Europe 479 (40.3) 419 (35.2) 399 (33.6) 408 (34.3)
Latin America 96 (8.1) 98 (8.2) 84 (7.1) 91 (7.7)
North America 129 (10.8) 146 (12.3) 137 (11.5) 138 (11.6)
Western Europe 305 (25.6) 329 (27.7) 395 (33.2) 346 (29.1)
Diabetes 542 (45.5) 510 (42.9) 495 (41.6) 499 (42.0) 0.06
Stroke 98 (8.2) 99 (8.3) 142 (12.0) 167 (14.1) <0.001
Hypertension 1,145 (96.2) 1,143 (96.1) 1,126 (94.7) 1,131 (95.1) 0.08
Prior myocardial infarction 267 (22.4) 340 (28.6) 217 (18.3) 252 (21.2) 0.01
Ischemic etiology of HF 453 (38.1) 454 (38.2) 380 (32.0) 426 (35.8) 0.036
New York heart association functional class <0.001
I 45 (3.8) 36 (3.0) 29 (2.4) 26 (2.2)
II 941 (79.1) 936 (78.7) 921 (77.5) 884 (74.4)
III 199 (16.7) 215 (18.1) 234 (19.7) 271 (22.8)
IV 4 (0.3) 2 (0.2) 5 (0.4) 7 (0.6)
Prior HF hospitalization 626 (52.6) 542 (45.6) 489 (41.1) 632 (53.2) 0.66
Body mass index, kg/m2 31.1  5.1 30.4  4.9 30.4  5.0 29.0  4.8 <0.001
Left ventricular ejection fraction, % 58.9  7.9 57.8  7.9 57.0  7.6 56.3  7.8 <0.001
Angiotensin-converting enzyme inhibitor or
angiotensin receptor blocker
1,072 (90.1) 1,014 (85.3) 1,013 (85.2) 1,006 (84.6) <0.001
Mineralocorticoid receptor antagonist 264 (22.2) 301 (25.3) 312 (26.2) 353 (29.7) <0.001
Diuretic agent 1,112 (93.4) 1,134 (95.4) 1,137 (95.6) 1,163 (97.8) <0.001
Beta-blocker 926 (77.8) 920 (77.4) 971 (81.7) 976 (82.1) 0.001
Atrial fibrillation at screening visit 11 (0.9) 122 (10.3) 658 (55.4) 745 (63.0) <0.001
Systolic blood pressure, mm Hg 132.1  15.2 131.3  15.3 128.7  15.1 130.0  16.0 <0.001
Diastolic blood pressure, mmHg 74.9  9.9 73.8  10.7 74.1  10.5 74.4  11.0 0.44
Potassium, mmol/l 4.5  0.4 4.5  0.4 4.5  0.4 4.5  0.5 0.11
Estimated glomerular filtration rate, ml/min/1.73 m2 67.3  19.8 63.0  18.7 61.6  18.1 58.1  18.4 <0.001
Values are range, mean  SD, or n (%).
HF ¼ heart failure; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; NYHA ¼ New York Heart Association.
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Cox proportional hazards regression models were
constructed for CV and all-cause death endpoints.
Continuous relationships between NT-proBNP level
and the primary endpoint were assessed using
restricted cubic splines. Using the same methods, we
performed a landmark analysis to assess the associa-
tion between change in NT-proBNP from before the
run-in period to week 16 and subsequent events
occurring after the week 16 visit. Changes in NT-
proBNP levels were calculated relative to the pre-
specified baseline measurement, which was
collected after screening and before the start
of the valsartan run-in period, in patients withavailable data at baseline and the subsequent time
point only.
All patients in the PARAGON-HF trial provided
written informed consent. Local ethics committees
and institutional review boards at each participating
site approved the study protocols. We performed
statistical analysis using STATA software v14.1
(StataCorp, College Station, Texas). A 2-sided
p value <0.05 was considered significant.
RESULTS
CLINICAL PROFILE AND OUTCOMES IN PATIENTS WITH
HIGHER OR LOWER SCREENING VISIT NT-proBNP.
FIGURE 1 Variation in Primary Endpoint Event Rate and Sacubitril/Valsartan Treatment Effect by Screening Visit NT-proBNP
The histogram represents NT-proBNP at screening visit. The solid line represents the estimated primary endpoint incidence rate (A) and rate
ratio for sacubitril/valsartan compared with valsartan (B) of the primary endpoint, total HF hospitalizations (Hosp) and CV death. The dashed
lines represent the 95% confidence intervals for the estimated incidence rate or rate ratio. The highest and lowest 3% of NT-proBNP values
are not shown. CV ¼ cardiovascular; HF ¼ heart failure; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; py ¼ patient-years;
Sac ¼ sacubitril; Val ¼ valsartan.
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FIGURE 2 Association Between Screening Visit NT-proBNP and Primary Endpoint
Event Rate in Patients With/Without AF and Obesity
(A) Relationship between screening NT-proBNP and the primary endpoint in patients with
ad without atrial fibrillation. (B) Same relationship in obese and non-obese patients. The
solid lines represent estimated continuous association of screening visit NT-proBNP with
the incidence rate primary endpoint, without adjustment. Dashed lines represent the
95% confidence intervals. The highest and lowest 3% of NT-proBNP values in each
subgroup are not shown. Atrial fibrillation was determined by the screening visit elec-
trocardiogram. Patients in atrial fibrillation were only included in the PARAGON-HF trial if
NT-proBNP was >600 pg/ml with recent HF hospitalization or >900 pg/ml without
hospitalization. Obesity was defined by body mass index >30 kg/m2. AF ¼ atrial
fibrillation; RR ¼ rate ratio; other abbreviations as in Figure 1.
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available in 4,757 (99.2%) of the 4,796 validly ran-
domized patients. Median NT-proBNP was 911 pg/ml
(25th to 75th percentiles: 464 to 1,613 pg/ml). The
baseline characteristics of patients in each quartile of
screening NT-proBNP are shown in Table 1. Patients
with higher NT-proBNP were older and more likely
male, with more prevalent atrial fibrillation and prior
stroke, worse NYHA functional class, and lower body
mass index, LVEF, and estimated glomerular filtra-
tion rate (all p # 0.002). Low atrial fibrillation prev-
alence in the lowest NT-proBNP quartile (1%) was due
to the higher NT-proBNP inclusion threshold for pa-
tients with atrial fibrillation.
Screening visit NT-proBNP strongly predicted the
primary endpoint, total HF hospitalizations and car-
diovascular death. In a multivariable recurrent
events regression model adjusted for 21 relevant
covariates, higher NT-proBNP was associated with a
greater risk of the primary endpoint (adjusted [adj.]
RR: 1.68 per natural log increase in NT-proBNP,
95% CI: 1.53 to 1.85; p < 0.001) (Figure 1A). Similar
elevations in risk were observed for secondary end-
points including all-cause death (adj. hazard ratio:
1.71, 95% CI: 1.55 to 1.89; p < 0.001), CV death (adj.
hazard ratio: 1.93, 95% CI: 1.71 to 2.18; p < 0.001), and
total HF hospitalizations (adj. RR: 1.61, 95% CI: 1.46
to 1.79; p < 0.001). The association between
screening visit NT-proBNP and the primary endpoint
was stronger in patients with atrial fibrillation (adj.
RR: 2.33 [95% CI: 1.89 to 2.87] in atrial fibrillation vs.
1.58 [95% CI: 1.42 to 1.75] not in atrial fibrillation; p
interaction <0.001) (Figure 2A). This interaction was
maintained when the analysis was restricted to pa-
tients whose NT-proBNP levels met inclusion criteria
regardless of atrial fibrillation status, and stratified
by HF hospitalization in the previous 9 months (adj.
RR: 2.39 [95% CI: 1.95 to 2.94] in atrial fibrillation vs.
1.50 [95% CI: 1.24 to 1.82] not in atrial fibrillation; p
interaction <0.001). Conversely, the association be-
tween NT-proBNP and the primary endpoints was
weaker in obese patients (adj. RR: 1.50 [95% CI: 1.31
to 1.71] in obese patients vs. 1.92 [95% CI: 1.70 to 2.17]
in nonobese patients; p interaction <0.001)
(Figure 2B). For a given NT-proBNP level, patients
with atrial fibrillation had lower event rates, and
obese patients had higher event rates, particularly at
the lower end of the NT-proBNP range, compared
with patients without atrial fibrillation and nonobese
patients, respectively.
NT-proBNP level at screening did not modify the
effect of sacubitril/valsartan compared with valsartan
on the primary endpoint (p interaction ¼ 0.96)
(Figure 1B) alone or after adjustment for significanttreatment interactions with LVEF and sex
(p interaction ¼ 0.82).
TRENDS IN NT-proBNP LEVELS DURING RUN-IN AND
FOLLOW-UP PERIODS. Changes in NT-proBNP were
assessed in the 2,774 patients (58% of validly
randomized patients) with available data at the pre
run-in visit, which was the pre-specified baseline
visit. Clinical characteristics of these patients were
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378similar to those without available data, except that
they were more likely to be Asian, less likely to have
been previously hospitalized or have atrial fibrilla-
tion, and had a higher screening visit NT-proBNP
level (all p < 0.01) (Supplemental Table 1).
Sacubitril/valsartan rapidly and reversibly
decreased NT-proBNP levels during the run-in and
post-randomization follow-up periods (Central
Illustration). Geometric mean NT-proBNP declined
5% during the valsartan run-in period, and a further
25% during the sacubitril/valsartan run-in period in
patients with available data at both time points. In
the first 16 weeks of treatment with study drug, NT-
proBNP increased 7% in the sacubitril/valsartan
group and 31% in the valsartan group. Compared with
valsartan, sacubitril/valsartan decreased NT-proBNP
by 19% (95% CI: 14% to 23%; p < 0.001) at 16 weeks,
adjusted for the pre–run-in value, in patients with
available data at both time points. At 48 weeks,
sacubitril/valsartan decreased NT-proBNP by 17%
(95% CI: 11% to 22%; p < 0.001) compared with val-
sartan, adjusted for the pre–run-in value. These
trends were consistent when considering only pa-
tients with available data at all time points
(Supplemental Figure 1).NT-proBNP reductions with sacubitril/valsartan
compared with valsartan at week 16 were similar in
men and women (20% and 18%, respectively), pa-
tients with LVEF # and > the median of 57% (20% and
18%, respectively), patients whose NT-proBNP at the
start of run-in was < and > the median (20% and 18%,
respectively), and obese and nonobese patients (20%
and 18%, respectively). Patients with atrial fibrillation
had smaller reductions in NT-proBNP levels with
sacubitril/valsartan compared with valsartan (11% for
patients in atrial fibrillation vs. 22% for patients not in
atrial fibrillation; p ¼ 0.02).
Patients whose NT-proBNP levels declined more
were at lower risk for subsequent HF hospitalizations
and CV death, regardless of treatment group. In a
landmark analysis of primary endpoints occurring
only after the week 16 visit, patients whose NT-
proBNP decreased from pre–run-in baseline to
16 weeks post-randomization were at lower subse-
quent risk (RR: 0.62 per log decrease in NT-proBNP,
95% CI: 0.54 to 0.71; p < 0.001), adjusted for pre–
run-in value and 21 clinical covariates (Figure 3). The
primary endpoint rate was 11.2 (95% CI: 8.7 to 14.5)
per 100 patient-years in the quartile of patients with
greatest NT-proBNP decline (>38%), and 15.8 (95% CI:
FIGURE 3 Association Between NT-proBNP Change and Rate of Subsequent Total HF
Hospitalizations and CV Death
The solid black line represents estimated incidence rate ratio of the primary endpoint,
total HF hospitalizations and CV death, occurring after 16 weeks, for patients at the
given NT-proBNP change, compared with no change in NT-proBNP level. The dashed
lines represent 95% confidence intervals for the estimated rate ratio. The highest and
lowest 3% of NT-proBNP change values are not shown. Abbreviations as in Figure 1.
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37913.1 to 19.1) per 100 patient-years in the quartile of
patients who had NT-proBNP increased >25%.
Adjusted reductions were similar for the components
of the primary endpoint, CV death alone (RR: 0.62 per
log decrease, 95% CI: 0.50 to 0.76; p < 0.001) and
recurrent HF hospitalizations (RR: 0.62 per log
decrease, 95% CI: 0.52 to 0.72; p < 0.001).
DISCUSSION
In contemporary patients with HFpEF enrolled in the
PARAGON-HF trial, we found that NT-proBNP at
screening strongly predicted risk of HF hospitaliza-
tions and CV death, but did not modify the treatment
effect of sacubitril/valsartan. Sacubitril/valsartan
consistently decreased NT-proBNP by 19% relative to
valsartan in men and women and in patients with
higher and lower LVEF. Patients who demonstrated
the greatest reduction in NT-proBNP had the best
subsequent outcomes. These data validate the prog-
nostic importance of NT-proBNP in this contemporary
HFpEF population and support consistent treatment
effects of sacubitril/valsartan in reducing NT-proBNP
levels overall and in key subgroups of patients with
HFpEF.
Consistent with previous observational studies and
clinical trials, we found that higher baseline NT-
proBNP was strongly associated with greater risk for
HF events (1,3). Event rates were lower in atrial
fibrillation and higher in obesity for a given NT-
proBNP level. Natriuretic peptide–based inclusion
criteria are now commonly used in HF trials to
confirm the diagnosis of HF and enrich for patients
with higher expected event rates, and patients in the
PARAGON-HF trial were required to have elevated
NT-proBNP. Atrial fibrillation and obesity both
confound the clinical diagnosis of HF (as alternative
causes of exercise intolerance) and affect natriuretic
peptide levels independently of risk (12–15). In the
PARAGON-HF trial, the minimum NT-proBNP
required for inclusion was 3 times higher in patients
with atrial fibrillation. Our findings support this
higher natriuretic peptide threshold. Indeed, an even
higher minimum in atrial fibrillation may be optimal,
as patients with atrial fibrillation and NT-proBNP just
above the minimum had relatively low event rates.
Conversely, a lower minimum NT-proBNP in obese
patients could also be useful, because obese patients
retained moderate risk even when NT-proBNP was
just above the minimum level required. Obesity-
related adjustment has been infrequently applied
due to the challenges of confirming HF diagnosis in
patients with low NT-proBNP but has been employed
in select HF device trials (Reducing Lung CongestionSymptoms in Advanced Heart Failure [RELIEVE-HF];
NCT03499236; and Cardiovascular Outcomes Assess-
ment of the MitraClip Percutaneous Therapy for
Heart Failure Patients With Functional Mitral Regur-
gitation [COAPT]; NCT01626079).
Patients with HFpEF and low NT-proBNP levels are
distinguished by a distinct clinical profile (younger
age, obesity, black race, with lower rates of atrial
fibrillation or chronic kidney disease). In prior post
hoc analyses from the I-Preserve (Irbesartan in
Heart Failure With Preserved Systolic Function) and
TOPCAT (Aldosterone Antagonist Therapy for Adults
With Heart Failure and Preserved Systolic Function)
studies, the study drug benefit (of irbesartan or spi-
ronolactone, respectively) was greater in patients
with lower natriuretic peptide levels at baseline
(16,17). It was hypothesized that these patients may
have less advanced disease, and their prognosis may
be more readily modifiable by neurohormonal ther-
apy. However, in the PARAGON-HF trial, we observed
that the modest overall treatment effects of sacubi-
tril/valsartan were consistent across the spectrum
of baseline NT-proBNP. The present analysis included
many more patients with available natriuretic peptide
data, which improved the precision of treatment
effect estimates. The efficacy of sacubitril/valsartan
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380in patients with a lower estimated glomerular filtra-
tion rate (who have higher NT-proBNP levels) and
with recent HF hospitalization may explain consis-
tent effects at higher natriuretic peptide ranges
(18,19).
Sacubitril/valsartan reduced NT-proBNP by 19%
compared with valsartan. This observation was
consistent with the phase II PARAMOUNT (Prospec-
tive Comparison of ARNI With ARB on Management
of Heart Failure With Preserved Ejection Fraction)
trial, which included w10% the sample size of the
PARAGON-HF trial and observed a 23% reduction in
NT-proBNP after 12 weeks (20). Of note, entry criteria
in the PARAMOUNT trial required higher baseline NT-
proBNP levels. In the PARAGON-HF trial, NT-proBNP
reduction occurred quickly and at submaximal doses
during the 2- to 4-week run-in period. This change
was reversible; after randomization, patients
continuing sacubitril/valsartan retained the NT-
proBNP improvement, whereas those randomized to
valsartan returned to pre-sacubitril/valsartan levels.
The magnitude of NT-proBNP reduction was lower
than in HF with reduced ejection fraction studies,
including the PARADIGM-HF (Prospective Compari-
son of ARNI With ACEI to Determine Impact on Global
Mortality and Morbidity in Heart Failure) (28% at 8 to
10 weeks compared with enalapril), EVALUATE-HF
(Study of Effects of Sacubitril/Valsartan vs. Enalapril
on Aortic Stiffness in Patients With Mild to Moderate
HF With Reduced Ejection Fraction) (33% at 12 weeks,
compared with enalapril), and PROVE-HF (Effects of
Sacubitril/Valsartan Therapy on Biomarkers,
Myocardial Remodeling and Outcomes) (30% at
14 days and 35% at 6 months, compared with baseline
values) trials (5–7).
Decreases in NT-proBNP in the early post-
randomization period were associated with lower
risk of the primary endpoint, consistent with prior
work (21). Interestingly, the 2 subgroups with lower
benefit for the primary outcome, men and patients
with higher LVEF, nevertheless had reductions in NT-
proBNP similar to women and patients with lower
LVEF. Thus, apparent differences noted in the clinical
effect of sacubitril/valsartan between sexes and across
the LVEF spectrum cannot be explained by differences
in effect on this natriuretic peptide. The relationship
between NT-proBNP reduction and outcomes was not
as strong as previously observed for patients with
heart failure with reduced ejection fraction in the
PARADIGM-HF trial. However, natriuretic peptide andclinical responses in individual subgroups may be
underpowered and need to be considered in the
context of a modest overall treatment benefit.
STUDY LIMITATIONS. First, screening visit NT-
proBNP was measured at affiliated regional labora-
tories using 2 different assays. Screening visit NT-
proBNP was used for risk modelling because all pa-
tients in the trial had available data. All assessments
of NT-proBNP change compared post-screening visit
samples that were analyzed in 2 fully harmonized
central laboratories with a single assay. The definition
of the pre–run-in period value as the baseline for
comparisons was pre-specified in the statistical
analysis plan. Second, we did not measure atrial
natriuretic peptide and C-type natriuretic peptide,
which are more direct substrates of neprilysin and
whose levels are dramatically altered by sacubitril/
valsartan in patients with HF with reduced ejection
fraction (4). Third, only 2% of patients in the
PARAGON-HF trial were black, so no conclusions
about this group with lower NT-proBNP could
be made.
CONCLUSIONS
Data from the PARAGON-HF trial affirm the strong
prognostic significance of NT-proBNP in forecasting
future risk of HF events in patients with HFpEF.
Greater reduction in NT-proBNP from baseline to
16-week post-randomization was associated with a
lower risk for adverse outcomes, regardless of treat-
ment group. Baseline NT-proBNP levels did not
significantly modify the effect of sacubitril/valsartan
on HF events. Sacubitril/valsartan reduced NT-
proBNP levels by 19%, and this reduction was
consistently observed in men and women, and pa-
tients with lower and higher LVEF, despite differ-
ences in clinical response between these groups. The
mechanisms by which neprilysin inhibition lowers
NT-proBNP in HFpEF require further study and may
be distinct from those that explain therapeutic ben-
efits on clinical outcomes.
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Solomon, Division of Cardiovascular Medicine,
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School, 75 Francis Street, Boston, Massachu-
setts 02115. E-mail: ssolomon@rics.bwh.harvard.edu.
Twitter: @JonWCunningham, @mvaduganathan,
@scottdsolomon.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In the
PARAGON-HF trial of sacubitril/valsartan compared with
valsartan in HFpEF, baseline NT-proBNP and change in
NT-proBNP over time strongly predicted HF events. The
modest reduction in HF events with sacubitril/valsartan
was similar in patients with higher and lower baseline NT-
proBNP. Sacubitril/valsartan reduced NT-proBNP by 19%
compared with valsartan.
TRANSLATIONAL OUTLOOK: Further studies are
needed to identify patients with HFpEF who benefit most
from sacubitril/valsartan and to investigate the mecha-
nisms of NT-proBNP reduction with neprilysin inhibition.
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